CRISPR-based innovations drove $21 billion in pharmaceutical licensing deals over five years: GlobalData – ET HealthWorld
London: The pharmaceutical industry has experienced a notable uptick in licensing agreements for innovator drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology over the past five years. These agreements, primarily concentrated in oncology, immunology, and central nervous system therapeutics, have collectively accumulated an impressive $21 billion in deal value. Furthermore, the period from … Read more
